Saudi Journal of Medicine and Public Health

https://saudijmph.com/index.php/pub

https://doi.org/10.64483/202522294

Integrative Approaches to Chronic Bronchitis Management: The Collaborative Role of Nursing, Laboratory Services, and Radiologists

Majed Shwiman Alshwiman [(1)] , Khulood Majed Hamoud Almutairi [(2)] , Bayan Abdullah Aloraibi [(3)] , Fatimah Mousa Ibrahim Alsekiny [(4)] , Ahmed Nasser Ali Hamdi [(5)] , Mohammed Eid S Aljohany [(6)] , Mohammed Abdulrahman M Abobaker [(6)] , Shroq Hadi Hassan Hamzi [(7)] , Hassan Ali Salman Muyidi [(8)] , Hussain Homod Habibi Namazi [(9)] , Sultan Mousa J Wasili [(10)]

(1) Security Forces Hospital - Riyadh, Ministry of Health, Saudi Arabia,
(2) Imam Abdul Rahman Alfaisal Hospital, Ministry of Health, Saudi Arabia,
(3) Hospital Imam Abdulrahman Al Faisal , Ministry of Health, Saudi Arabia,
(4) Irada Mental Health Hospital, Ministry of Health, Saudi Arabia,
(5) Ministry Of Health, Alharth General Hospital, Saudi Arabia,
(6) Ministry Of Health, Saudi Arabia,
(7) Comprehensive Specialized Clinics For The Security Forces In Hail Ministry Of Interior , Saudi Arabia,
(8) Abu Arish General Hospital,Ministry of Health, Saudi Arabia,
(9) Sabya General Hospital Branch - JIZAN, Ministry of Health, Saudi Arabia,
(10) Abuareash General Hospital, Ministry of Health, Saudi Arabia

Abstract

Background: Chronic Bronchitis (CB) and its pediatric counterpart, Protracted Bacterial Bronchitis (PBB), are chronic respiratory conditions characterized by persistent cough and mucus hypersecretion. Driven by neutrophilic inflammation and often environmental exposures, these conditions pose significant long-term risks, including progression to COPD, bronchiectasis, and increased cardiovascular mortality, underscoring the need for proactive, integrated management.

Aim: This article aims to outline a collaborative, interprofessional framework for managing CB and PBB, emphasizing the synergistic roles of pharmacists, laboratory services, and radiologists in improving patient outcomes from diagnosis through long-term care.

Methods: The proposed model integrates structured clinical pathways. Pharmacists conduct frontline screening, optimize medication regimens (e.g., antibiotics, inhalers), and lead smoking cessation efforts. Laboratory services provide crucial microbiological data to guide antibiotic selection and monitor treatment response. Health administrators design and implement standardized protocols, registries for high-risk patients, and performance metrics to ensure care quality and coordination.

Results: This collaborative approach facilitates early and accurate diagnosis, ensures guideline-concordant treatment (including the critical 2-week antibiotic course for PBB), and enhances patient education and adherence. It leads to reduced exacerbations, slower lung function decline, and more efficient resource utilization by streamlining workflows and preventing treatment delays.

Conclusion: Effective management of chronic bronchitis requires a unified systems-based approach. By leveraging the distinct expertise of pharmacists, laboratory professionals, and administrators within a coordinated model, healthcare systems can transform the management of these conditions from reactive to proactive, ultimately improving long-term respiratory health and reducing mortality.

Keywords: Chronic Bronchitis, Protracted Bacterial Bronchitis, Interprofessional Collaboration, Pharmacist, Antimicrobial Stewardship, Healthcare Administration, Mucus Hypersecretion.

Introduction

A persistent cough producing sputum for at least 3 months annually over 2 consecutive years characterizes chronic bronchitis in adults. Goblet cell hyperplasia leads to excessive mucus production. This, combined with reduced mucus clearance, causes airway inflammation, structural changes, and obstruction. Characteristically, chronic bronchitis in children is due to persistent neutrophilic airway inflammation driven by chronic bacterial infection of the airways [1]. For this reason, experts use the term "protracted bacterial bronchitis" [1]. The defining features of protracted bacterial bronchitis (PBB) are an isolated chronic wet cough lasting longer than 4 weeks, resolution with a 2-week course of appropriate antibiotic treatment, and the absence of evidence indicating an alternative cause. Chronic bronchitis in childhood can persist into adulthood, and proper management is imperative as progression to bronchiectasis, asthma, and lung function impairment

*Corresponding author e-mail: Majedshwiman@gmail.com (Majed Shwiman Alshwiman).

Receive Date: 06 November 2025, Revise Date: 30 November 2025, Accept Date: 02 December 2025

is possible [1]. In addition, studies reveal that a chronic productive cough in young adults 18 to 30 results in an increased risk of future cardiovascular events and premature deaths, likely due to systemic inflammation [2]. Likewise, childhood asthma and allergies are risk factors for chronic bronchitis in adults. Despite being a common finding in patients with chronic obstructive pulmonary disease (COPD), chronic bronchitis can be an isolated illness with or without airflow obstruction [3]. However, patients with isolated chronic bronchitis are at risk factor for developing airflow obstruction, accelerated lung function decline, COPD exacerbations, and increased lung disease-related and all-cause mortality [4][5][6]. In adults, a strong causal relationship with smoking exists; however, many cases of chronic bronchitis are not associated with smoking, indicating additional risk factors. Hard-rock mining, tunnel work, concrete manufacturing, non-mining industrial work, exposure to biomass fuel burning, and livestock farming are all well-known underlying causes explaining the presence of chronic bronchitis in patients who have never smoked. Treatment of chronic bronchitis centers around reducing mucus production, improving mucus clearance, minimizing inflammation, and supporting effective cough mechanisms. Smoking cessation and secondhand smoke avoidance are critical for reducing airway damage and improving respiratory health. Clinicians tailor the management of acute exacerbations based on symptoms with antibiotics, short-acting bronchodilators, and systemic corticosteroids. Patient education regarding self-management and, when available, pulmonary rehabilitation are additional essential management components. Children with PBB require a minimum of 2 weeks of antibiotics, adjusted based on symptom resolution and guideline specifics [7][8][9]. Chronic bronchitis and PBB significantly affect long-term lung function and overall mortality. Healthcare professionals should proactively manage these conditions, utilizing a well-balanced combination of pharmacologic and non-pharmacologic therapies.

Pharmacists' Role in Chronic Bronchitis and PBB

Pharmacists occupy a pivotal position at the interface of diagnosis, therapy, and patient self-management for both adult chronic bronchitis and pediatric PBB. In community and ambulatory settings, they screen for chronic cough duration, sputum characteristics, environmental exposures, and red flags that warrant referral, thereby shortening time-to-diagnosis for PBB in children and identifying adults at risk of progression to COPD or bronchiectasis [1][3]. During acute exacerbations, pharmacists optimize short-acting bronchodilator regimens, ensure appropriate inhaler technique, and reconcile systemic corticosteroid courses to minimize cumulative adverse effects while maintaining efficacy [7][8]. In antibiotic stewardship, pharmacists evaluate spectrum, dose, and duration consistent with guideline-concordant care—particularly the minimum two-week course for PBB—while monitoring for early clinical response and adverse events that might necessitate regimen adjustment [7][9]. Beyond acute care, pharmacists lead smoking cessation interventions using motivational interviewing and pharmacotherapies, a cornerstone for mitigating airway inflammation and excess mucus production in adult chronic bronchitis [3][4]. They also deliver adherence coaching for long-term mucoregulators, vaccinations, and comorbidity medications, recognizing that systemic inflammation associated with chronic productive cough may amplify cardiovascular risk in young adults [2]. Within multidisciplinary teams, pharmacists translate laboratory data into practical regimen modifications, close loop communication with prescribers, and implement action plans patients can use to self-manage fluctuations in symptoms [5][6].

Laboratory Diagnostics and Monitoring

Laboratory services underpin accurate classification, exclusion of mimics, and monitoring of treatment response. For suspected PBB, targeted microbiological assessment of airway secretions supports identification of likely pathogens driving neutrophilic inflammation, guiding antibiotic selection and duration while avoiding unnecessary broad coverage [1][7]. In adults with chronic bronchitis, sputum characterization and inflammatory markers can contextualize symptom burden, while serial assessments help detect transition toward airflow obstruction or exacerbation-prone phenotypes [3][4]. When children present with chronic wet cough beyond four weeks, coordinated laboratory testing complements clinical criteria to confirm PBB and to document resolution following the prescribed antibiotic course, reinforcing the defining features of this entity [1]. In occupationally exposed nonsmokers, laboratory input harmonizes with exposure histories to differentiate irritant-induced mucus hypersecretion from infectious or allergic contributors, informing tailored mitigation strategies [3]. Longitudinal data stewardship by the laboratory—standardized collection, processing, and reporting—enables administrators and clinicians to construct dashboards tracking cough duration, pathogen patterns, antibiotic days of therapy, and relapse rates, improving resource allocation and quality improvement targeting [8][9]. Crucially, laboratory participation in antimicrobial stewardship committees ensures that susceptibility trends and turnaround times directly drive evidence-based updates to empirical pathways for both adult and pediatric care [7].

Health Administration, Care Pathways, and Quality

Effective management of chronic bronchitis and PBB depends on administrative scaffolding that integrates pharmacy, laboratory, and clinical services into reliable care pathways. Health administrators design standardized protocols that embed early identification prompts in primary care workflows, define roles for pharmacists in triage and education,

and specify laboratory triggers for culture acquisition and follow-up, thereby reducing unwarranted variation [1][3]. Given the elevated risks of accelerated lung function decline and mortality in chronic bronchitis—even when airflow obstruction is not initially evident—administrative oversight prioritizes registries to track high-risk adults and transitions of care after exacerbations [4][5][6]. For pediatrics, administrators can codify the two-week antibiotic standard for PBB into order sets and discharge materials, aligning prescribers and caregivers on the duration required for full symptom resolution and minimizing premature discontinuation [7][9]. Performance metrics may include time from presentation to cough resolution, adherence to antibiotic duration, documented inhaler technique checks, and smoking cessation follow-up contacts, all linked to pharmacist- and laboratory-led interventions [3][8]. Moreover, incorporating environmental and occupational histories into electronic records allows systems to identify clusters associated with biomass exposure or industrial dusts, informing community-level prevention programs and counseling delivered by pharmacists and respiratory educators [3]. Administrators also champion pulmonary rehabilitation access and patient self-management curricula, recognizing their importance for functional outcomes and sustained symptom control across care settings [8].

Integrated Pharmacist–Laboratory–Administration Model

An integrated model weaves together pharmacist-led assessment, laboratory-enabled precision, and administrative standardization to deliver timely, guideline-concordant care. In the initial encounter, pharmacists use structured cough timelines and exposure screens to flag likely PBB in children and chronic bronchitis in adults, prompting appropriate laboratory evaluation and referral when indicated [1][3]. Once laboratory data are available, pharmacists interpret results in collaboration with clinicians, reconciling antibiotic selection and duration for PBB and calibrating anti-inflammatory and bronchodilator therapy for adult chronic bronchitis, including education on device technique and action plans for exacerbations [7][8][9]. Health administration ensures these steps are embedded in electronic pathways with decision support, auto-generated follow-up tasks, and outcome dashboards that monitor relapse, antibiotic days, and lung function trajectories, thereby addressing the documented risks of progression and mortality [4][5][6]. This triad extends to prevention: pharmacists operationalize smoking cessation protocols; laboratories monitor pathogen trends to refine stewardship; and administrators resource pulmonary rehabilitation and community exposure reduction initiatives, a comprehensive response to the multifactorial nature of chronic bronchitis across the lifespan [2][3]. By aligning these domains, systems can deliver the two-week antibiotic benchmark for PBB reliably, curtail unnecessary broad-spectrum use, and ensure adults receive consistent counseling on environmental risk mitigation and self-management, translating pathobiologic insights—goblet cell hyperplasia, mucus stasis, and neutrophilic inflammation—into measurable improvements in symptoms and function [1][7][9].

Etiology

Chronic bronchitis arises from sustained injury to the airways caused by inhaled and aspirated irritants that initiate mucus hypersecretion, impair mucociliary clearance, and perpetuate neutrophilic inflammation. Among these, cigarette smoking remains the dominant etiologic agent, with a cumulative 30-year incidence of 42% among current smokers, underscoring a potent dose–response relationship between tobacco exposure and chronic productive cough [10]. Yet the condition is not exclusive to smokers: between 4% and 22% of affected individuals report never smoking, a finding that compels clinicians to appraise a broader array of environmental, occupational, genetic, and host-related determinants when evaluating persistent sputum-producing cough [10]. In such cases, airway injury reflects a combination of epithelial damage from non-tobacco toxicants, heightened oxidative stress, and recurrent microbial colonization that together remodel the bronchial wall and increase goblet cell number, culminating in the clinical phenotype of chronic bronchitis. A robust body of epidemiologic and mechanistic research implicates workplace exposures to gases, mineral dusts, fumes, and organic solvents as independent drivers of chronic bronchitis, even in people without spirometric evidence of COPD [11][12]. Inhalation of these agents provokes chronic irritation of conducting airways, amplifies mucous gland hypertrophy, and promotes low-grade inflammation that may be clinically silent until recurrent infections or seasonal exposures unmask symptoms [11][12]. The etiologic landscape extends beyond the industrial setting to the household environment, particularly in low-resource contexts where biomass fuels—including wood, dung, and crop residues—are burned for cooking and heating. Prolonged exposure, often borne disproportionately by women due to time spent near indoor stoves, increases risk for both COPD and chronic bronchitis via sustained particulate and carbonyl compound exposure that overwhelms epithelial antioxidant defenses and slows ciliary beat frequency [13]. These insights emphasize the importance of exposure histories that capture both formal employment and domestic fuel use, since risk accrues cumulatively across settings.

Genetic susceptibility modulates individual risk, explaining why similar exposures yield heterogeneous clinical outcomes. Associations

between chronic mucus hypersecretion and a single nucleotide polymorphism on chromosome 3, as well as a significant locus at chromosome 11p15.5 linked to COPD and chronic bronchitis, suggest that airway defense pathways and mucus regulation are under meaningful genetic control [14]. Such variants may influence mucin gene expression, innate immune signaling, and repair mechanisms after epithelial injury, thereby lowering the threshold at which environmental irritants translate into persistent disease [14]. Additional host and contextual factors further shape etiology, including ambient air pollution, antecedent or coexisting asthma, gastroesophageal reflux with microaspiration, recurrent respiratory infections across the lifespan, chronic aspiration from neurologic or esophageal disorders, and atopic disease; each contributes to epithelial inflammation, mucus stasis, and cough hypersensitivity that reinforce the chronic bronchitic state [15][16][17]. In children, the etiologic paradigm differs: impaired mucociliary clearance and airway malacia predispose to chronic infection with nontypeable *Haemophilus influenzae*, *Streptococcus pneumoniae*, and *Moraxella catarrhalis*, defining protracted bacterial bronchitis (PBB) as a distinct, infection-driven entity that nonetheless shares the key pathophysiologic features of mucus overproduction and neutrophilic inflammation [18]. Collectively, these data position chronic bronchitis as a multifactorial disorder emerging from convergent irritant exposures, genetic predisposition, and host comorbidities, with pediatric PBB highlighting the centrality of persistent bacterial infection when structural and clearance defenses are compromised [10][11][12][13][14][15][16][17][18].



Figure-1: Chronic bronchitis and healthy lungs.

Epidemiology

Chronic bronchitis represents one of the leading causes of chronic cough worldwide, though its true prevalence is likely underestimated due to underreporting and limited healthcare-seeking behaviors among affected individuals. Many smokers, for instance, normalize their cough and sputum production as a natural consequence of tobacco use, resulting in missed opportunities for early diagnosis and intervention. Consequently, epidemiologic studies on chronic cough often reveal a chronic bronchitis incidence of 5% or less, despite clinical data suggesting a substantially higher burden within the general population [19]. Globally, the prevalence of chronic bronchitis is estimated to range between 3% and 22%, varying according to population characteristics, diagnostic criteria, and regional exposure patterns. Within the cohort of individuals diagnosed with chronic obstructive pulmonary disease (COPD), an average of 27% to 35% exhibit chronic bronchitis as a prominent or overlapping phenotype [20]. This overlap highlights the heterogeneity of COPD and reinforces the understanding that chronic bronchitis can either exist independently or coexist as part of a broader spectrum of obstructive airway disease. In the United States, approximately 10 million individuals are affected by chronic bronchitis, with the majority falling within the 44 to 65 age range. Notably, nearly one-third (31%) of cases occur among younger adults aged 18 to 44, a finding that challenges the traditional perception of chronic bronchitis as a disease confined to older smokers [20]. Several demographic and clinical determinants are strongly associated with increased incidence and disease persistence. These include active smoking, older age, progressive COPD severity, and comorbid conditions such as asthma and obstructive sleep apnea. Epidemiologic analyses also demonstrate higher prevalence among females, a pattern possibly linked to heightened airway reactivity, occupational exposures, and differences in inflammatory response [21][22]. Racial and ethnic disparities are evident as well, with elevated rates documented among non-Hispanic Black and non-Hispanic White populations, suggesting complex interactions between socioeconomic status, occupational exposure, healthcare access, and smoking prevalence [23].

In pediatric populations, protracted bacterial bronchitis (PBB**)** constitutes the most common etiology of chronic wet cough in children under five years old, accounting for nearly 40% of all referrals to pediatric pulmonology clinics [18][24]. The disorder predominantly affects male children, with median ages of onset reported between 1.8 and 4.8 years, although cases in older adolescents have been described, indicating that PBB can persist or recur beyond early childhood [24]. Multiple environmental and social factors modulate susceptibility to PBB, including attendance at childcare facilities—where close contact promotes bacterial transmission—alongside a prior history of chronic cough or wheezing within the preceding year. Additionally, living in crowded households, exposure to environmental irritants, and experiencing homelessness are notable risk amplifiers that compromise airway hygiene and immunity [1][25]. Collectively, these epidemiologic patterns portray chronic bronchitis and PBB as multifactorial public health challenges influenced by behavioral, demographic, and environmental determinants that intersect across the lifespan, necessitating both targeted prevention strategies and early clinical

recognition to mitigate long-term respiratory morbidity.

Pathophysiology

Chronic bronchitis represents a progressive airway disorder in which structural, inflammatory, and cellular mechanisms converge to produce chronic mucus hypersecretion and airflow obstruction. In adults, repeated exposure to cigarette smoke, chronic or recurrent viral and bacterial infections, and other toxic environmental stimuli initiate a cascade of mucosal injury that promotes mucus overproduction and persistent airway inflammation. These noxious exposures stimulate epithelial and immune cells to release inflammatory mediators and activate humoral pathways that drive mucin secretion as a defensive response intended to protect the airway from irritants. However, when sustained, this defense becomes pathologic. One of the principal mechanisms underpinning this process involves the activation of the epidermal growth factor receptor (EGFR) pathway in airway epithelial cells. Inflammatory cells, particularly neutrophils, release mediators that upregulate EGFR expression, triggering downstream mucin gene transcription and ultimately resulting in mucous gland hypertrophy, goblet cell metaplasia, and excessive mucus secretion [26]. EGFR activation and the accompanying neutrophil infiltration represent the molecular core of mucus hypersecretion in chronic bronchitis [26]. Under physiologic conditions, apoptotic neutrophils are efficiently cleared by macrophages, maintaining homeostasis within the airway environment. In patients with chronic bronchitis or COPD, however, persistent oxidative stress and inflammatory conditions disrupt this clearance mechanism, promoting neutrophil necrosis instead of apoptosis. This leads to the release of neutrophil-derived proteases, including elastase, and reactive oxygen species (ROS), both of which amplify tissue injury and mucus production. Neutrophil elastase is especially critical: it not only directly stimulates goblet cell degranulation but also cleaves the proligand form of transforming growth factor (TGF)-α, thereby releasing mature TGF-α to activate EGFR in a ligand-dependent manner [27]. In addition, neutrophils secrete tumor necrosis factor (TNF)-α, which upregulates EGFR expression, while the generated ROS further activate the receptor via oxidative signaling. This self-reinforcing cycle of neutrophil recruitment, degranulation, and EGFR stimulation perpetuates chronic mucus hypersecretion and epithelial remodeling that defines the disease.

The mucus itself becomes pathologically altered in both volume and composition. Normally, airway mucus is composed of 97% water and 3% solids, including mucins, proteins, and cellular debris. Two principal mucin polymers—MUC5AC and MUC5B—form the structural framework of airway mucus. In chronic bronchitis, there is a significant overproduction of MUC5B due to submucosal gland hyperplasia, while cigarette smoke, interleukin-13 (IL-13), air pollutants, allergens, and viral infections further increase MUC5AC synthesis through activation of the EGFR signaling cascade [28][29]. The overexpression of MUC5AC in current smokers correlates strongly with exacerbation frequency, symptom severity, and accelerated decline in lung function, linking molecular abnormalities to clinical outcomes. The resultant mucus becomes more viscous and difficult to clear, compromising mucociliary transport and allowing pathogens and inflammatory debris to accumulate. As mucous metaplasia progresses, the thickened epithelial cell layer and excess mucus obstruct airflow, particularly during expiration. Altered airway surface tension from mucus accumulation predisposes the bronchi to collapse, leading to air trapping and ventilation–perfusion mismatch. Ineffective clearance further predisposes the airway to bacterial colonization, establishing a vicious cycle of infection and inflammation that sustains disease progression. Chronic cough and sputum production, hallmark features of chronic bronchitis, not only reflect these ongoing processes but also independently predict future development of COPD, even among individuals without baseline airflow limitation [30]. Notably, longitudinal studies indicate that adults younger than 50 years with chronic bronchitis symptoms face an increased risk of future COPD, cardiovascular disease, and all-cause mortality, underscoring the systemic inflammatory burden associated with persistent airway disease [30].

In pediatric populations, the pathophysiologic framework shifts toward an infection-centered model known as protracted bacterial bronchitis (PBB**)**. In these children, early insults such as viral bronchiolitis or bacterial pneumonia disrupt normal mucociliary defenses, leading to chronic bacterial colonization and biofilm formation within the airways [31]. Biofilms are complex communities of bacteria embedded in a self-produced extracellular matrix that shields microbes from both host immune responses and antibiotics, rendering infections difficult to eradicate. The persistence of these biofilms triggers chronic neutrophilic inflammation and sustained mucus overproduction. Environmental exposures, such as passive tobacco smoke or air pollution, further impair ciliary function and epithelial repair, compounding mucus stasis and infection risk. Genetic susceptibilities, maternal smoking, and recurrent lower respiratory tract infections during infancy also contribute to weakened innate defenses, setting the stage for chronic bacterial persistence. Ultimately, whether in adults or children, chronic bronchitis represents the end result of maladaptive repair processes in response to repeated injury. Central to its pathogenesis are neutrophil-driven inflammation, EGFR-mediated mucin overexpression, and impaired clearance mechanisms that together sustain mucus

hypersecretion and airway obstruction [26][27][28][29][30][31]. This integrated model highlights the need for therapeutic strategies that target not only airway inflammation but also mucus rheology, microbial biofilms, and the molecular regulators of mucin production to prevent progression toward irreversible obstructive lung disease.



Figure-2: Pathophysiology of chronic bronchitis.

Histopathology:

The histopathological characteristics of chronic bronchitis reflect the cumulative effects of prolonged airway irritation, inflammation, and mucus gland remodeling. Gross pathological examination typically reveals a boggy, hyperemic mucosa lined with thick, mucinous secretions that often contain pus and inflammatory exudates. The bronchial walls appear swollen and irregular, and the openings of the mucous glands are accentuated by visible bronchial pits filled with excessive mucus. These findings represent the macroscopic correlate of the chronic inflammatory and secretory processes occurring within the airway epithelium and submucosa. In severe cases, the lumen may be partially obstructed by mucus plugs, leading to air trapping and distal atelectasis, while the surrounding lung tissue often demonstrates patchy hyperinflation secondary to impaired airflow. On microscopic examination, the earliest histologic changes involve mucus hypersecretion within the large airways, accompanied by hypertrophy and hyperplasia of the submucosal glands located in the trachea and bronchi. These structural modifications reflect an adaptive yet ultimately pathologic attempt by the epithelium to increase mucus production as a protective mechanism against persistent irritants, such as tobacco smoke and environmental toxins. Over time, continued inflammation induces squamous metaplasia and epithelial dysplasia, particularly in the smaller bronchi and bronchioles, where goblet cell numbers increase markedly, contributing to the excessive mucus burden and impaired mucociliary clearance. The lamina propria and submucosa become infiltrated with chronic inflammatory cells, predominantly lymphocytes, plasma cells, and neutrophils, reinforcing the chronic inflammatory milieu that sustains tissue injury. A hallmark morphologic feature used to quantify these changes is the Reid index, a histopathological measurement expressing the ratio of the thickness of the mucous gland layer to the distance between the epithelium and the cartilage. In healthy airways, this ratio is less than 0.4; however, in patients with chronic bronchitis, the index is significantly elevated, indicating glandular enlargement and submucosal expansion due to persistent mucus hypersecretion [32]. This enlargement corresponds with the clinical severity of sputum production and airflow limitation. As the disease advances, peribronchial fibrosis and smooth muscle hypertrophy may develop, further narrowing the airway lumen and contributing to chronic obstruction. Collectively, the histopathological profile of chronic bronchitis demonstrates a progression from reversible mucous gland hypertrophy and epithelial irritation to irreversible airway remodeling, dominated by glandular proliferation, goblet cell metaplasia, and chronic inflammation. These microscopic findings not only define the disease morphologically but also explain its clinical manifestations—persistent cough, sputum overproduction, and airflow limitation—underscoring the direct correlation between structural pathology and functional impairment in chronic bronchitis [32].

History and Physical

A thorough history and physical examination remain central to the evaluation of suspected chronic bronchitis, integrating symptom chronology, exposure assessment, comorbidities, and the exclusion of alternative diagnoses. The clinical picture often unfolds gradually, beginning with a productive cough that patients may minimize or attribute to smoking or seasonal colds, which delays presentation. Clarifying the duration and pattern of cough and sputum production is essential, as the classic definition requires cough with sputum for at least three months per year over two consecutive years. A detailed exposure history should probe for cigarette and secondhand smoke, biomass fuels, occupational inhalants, ambient air pollution, and prior respiratory infections, alongside inquiry into gastroesophageal reflux, asthma, allergic disease, and sleep-disordered breathing. Because symptom burden can oscillate, eliciting the presence of exacerbation triggers—viral illnesses, weather shifts, and environmental irritants—helps distinguish baseline disease from acute decompensations. Functional impact is equally important: patients frequently report activity limitation, work absenteeism, and social withdrawal, and they may endorse sleep fragmentation from nocturnal cough. Screening for depression and anxiety

is warranted given the bidirectional relationship between respiratory symptoms and mental health. Physical examination, while sometimes unrevealing in mild disease, can still provide clues to severity, complications, and comorbid conditions, especially when assessed during or shortly after exacerbations [33].

Clinical Features in Adults

In adults, the signature complaint is a chronic, productive cough, with sputum typically mucoid and clear to white at baseline. Color change to yellow or green, new malodor, fever, or pleuritic pain heightens concern for superimposed infection such as acute bronchitis, sinusitis, or bronchiectasis. Dyspnea emerges variably, often exertional at first, and may precede or follow the development of airflow limitation when chronic bronchitis coexists with COPD. Wheeze, chest tightness, presyncope or syncope during paroxysms of cough, fatigue, and weight fluctuations reflect the interplay of ventilatory mechanics, deconditioning, and the metabolic cost of breathing. Some patients gain weight as activity declines from exertional dyspnea; others lose weight due to early satiety, breathlessness during meals, and catabolic stress. Psychological symptoms are common, driven by symptom unpredictability and social constraints. On examination, mild disease may manifest only subtle end-expiratory wheeze or a prolonged expiratory phase, particularly with forced maneuvers. As severity increases, signs of hyperinflation accumulate, including increased resonance to percussion, diminished breath and heart sounds, low diaphragms, and dependent or basilar crackles that may vary with cough as secretions shift within the airways [33]. Advanced disease can reveal accessory muscle recruitment, suprasternal retractions, pursed-lip breathing, and the Hoover sign—paradoxical inward movement of the lower lateral rib cage during inspiration—indicating significant hyperinflation and diaphragmatic flattening. Cyanosis may signal hypoxemia, while hepatomegaly and jugular venous distension can reflect cor pulmonale from chronic hypoxic pulmonary vasoconstriction. Asterixis, if present, suggests hypercapnic encephalopathy in the setting of ventilatory failure [34]. Importantly, digital clubbing is atypical for COPD and should prompt investigation for alternative or concomitant pathology such as lung cancer, bronchiectasis, interstitial lung disease, or cyanotic congenital heart disease.

Acute exacerbations represent inflection points in the clinical course, ranging from modest symptom upticks to life-threatening respiratory failure. The cardinal exacerbation triad—worsening dyspnea, increased cough, and augmented sputum volume or purulence—often accompanies tachypnea and tachycardia. Patients with impaired baseline reserve may rapidly decompensate with dynamic hyperinflation, ventilation–perfusion mismatch, and rising work of breathing, culminating in acute respiratory acidosis and hypoxemia. Bedside clues to severity include use of accessory muscles, inability to speak full sentences, altered mentation from hypercapnia or hypoxemia, and asterixis indicating carbon dioxide retention. Distinguishing exacerbations of chronic bronchitis from heart failure, pulmonary embolism, and pneumonia requires careful synthesis of history, examination, and targeted testing; nevertheless, the physical examination remains the first indicator guiding immediate triage and therapy [34].



Figure-3: Symptoms of bronchitis.

Clinical Features in Children

In children, the clinical paradigm differs, with protracted bacterial bronchitis (PBB) dominating the differential for chronic wet cough. Parents typically report a persistent, moist-sounding cough lasting at least four weeks, often worse at night or with viral intercurrent illnesses, and sometimes transiently responsive to short antibiotic courses. Unlike conditions such as sinusitis or otitis media, PBB lacks consistent upper airway features and generally does not present with digital clubbing or thoracic deformity, findings that would raise suspicion for bronchiectasis, cystic fibrosis, or primary ciliary dyskinesia. On auscultation, clinicians more often detect coarse breath sounds or inspiratory crackles that may partially clear after coughing, while wheeze—although frequently reported by caregivers—is less commonly appreciated during the visit. The remainder of the examination is frequently normal, and growth parameters are usually preserved unless cough severity has led to significant sleep disruption, feeding difficulties, or recurrent antibiotic exposure affecting appetite. Because PBB is driven by bacterial infection in the context of impaired mucociliary clearance, careful attention to environmental exposures such as secondhand smoke and air pollutants is critical, as these factors exacerbate epithelial injury and mucus stasis. Early recognition and guideline-concordant antibiotic therapy are essential both for symptom resolution and to prevent

progression to suppurative lung disease. The pediatric history should also probe for recurrent lower respiratory tract infections, prematurity, aspiration risks, and immune or anatomic conditions that predispose to persistent bacterial colonization. Taken together, the adult and pediatric clinical profiles underscore the value of meticulous history-taking and targeted examination to differentiate chronic bronchitis and PBB from their mimics, stratify risk, and guide timely, effective management across the age spectrum [18].

Evaluation

A comprehensive evaluation of suspected chronic bronchitis begins with meticulous history-taking and a targeted physical examination, as these steps often delineate the likely etiologies and guide efficient testing. Clinicians should document constitutional symptoms such as fever, night sweats, or unintentional weight loss, which may point toward chronic infection, systemic inflammatory disorders, or malignancy. Characterizing cough quality and sputum is essential: purulent sputum raises concern for concomitant pulmonary or sinonasal infection, whereas hemoptysis—whether streaking or frank bleeding—necessitates prompt consideration of cancer, infection, or foreign body aspiration. Dyspnea should be probed for onset, triggers, and progression, because exertional breathlessness may reflect airflow obstruction, hyperinflation, or parenchymal disease. Importantly, patients who are immunosuppressed—owing to primary immunodeficiency, HIV infection, chemotherapy, systemic corticosteroids, or biologics—carry heightened risk for infectious causes of chronic cough and therefore warrant a lower threshold for focused microbiologic testing and imaging to exclude atypical pathogens and opportunistic processes [7]. Beyond symptom characterization, exposure and comorbidity inventories are central. A thorough history includes perinatal and birth events, family history of respiratory and immunologic disease, and any choking episodes suggesting aspiration. Prior diagnoses and infections—particularly asthma, HIV, tuberculosis, or recurrent pneumonias—should be reviewed alongside smoking status (active, former, secondhand) and detailed environmental and occupational exposures to chemicals, dusts, fumes, or biomass fuels, which have independent associations with chronic bronchitic symptoms and progression. Medication review must be exacting: angiotensin-converting enzyme inhibitors can provoke or perpetuate cough, and a structured four-week discontinuation trial is recommended before embarking on extensive diagnostic workups when clinically safe to do so [7]. Agents that exacerbate gastroesophageal reflux—such as bisphosphonates and calcium channel blockers—should also be identified, as reflux-related microaspiration can sustain cough and mucus hypersecretion in susceptible patients. Parallel screening for upper airway contributors (allergic or vasomotor rhinitis, chronic rhinosinusitis) and for sleep-disordered breathing further refines the differential diagnosis and influences testing priorities.

Imaging and physiologic testing are deployed judiciously based on symptom duration and pretest probabilities. In adults with cough persisting beyond eight weeks—and in children with cough beyond four weeks—a chest radiograph is generally indicated, with narrow exceptions for clearly defined asthma or upper-airway cough syndrome due to postnasal drip, acute sinusitis, vasomotor rhinitis, or allergic rhinitis when the clinical picture is unequivocal [7]. Chest radiography may reveal hyperinflation, bronchitic markings, or alternative diagnoses; however, a normal film does not exclude relevant pathology. Computed tomography (CT) of the chest is reserved for cases with radiographic abnormalities requiring clarification or when clinical suspicion for occult disease (e.g., malignancy, bronchiectasis) remains high despite a normal radiograph. Pulmonary function testing (spirometry with pre- and post-bronchodilator measurements) is essential to assess for airflow obstruction, bronchodilator responsiveness, and coexisting asthma or COPD; these tests apply to adults and to children aged three years and older when feasible, and they help stage severity, track progression, and guide pharmacotherapy [7][35]. In pediatrics, the evaluation must explicitly consider protracted bacterial bronchitis (PBB), which is diagnosed primarily on clinical grounds. Four criteria anchor this diagnosis: a chronic wet cough persisting for ≥4 weeks; an evaluation that fails to reveal alternative causes (including normal spirometry and chest radiography, recognizing that peribronchial accentuation on radiographs can be acceptable); absence of signs or symptoms pointing to competing diagnoses; and resolution of cough following a two-week course of appropriate antibiotics [36]. Because PBB is defined by response to therapy, clinicians should ensure antibiotic selection aligns with local microbiology and guidelines, and they should arrange follow-up to confirm symptom resolution. Bronchoscopy is not routinely required to establish PBB but becomes appropriate when features are atypical, when there is a suspicion of an inhaled foreign body, or when an adequate antibiotic trial fails to produce clinical improvement. In such scenarios, bronchoscopy with bronchoalveolar lavage (BAL) and quantitative cultures can direct organism-specific therapy and uncover alternative pathology [36].

Recurrent or refractory pediatric disease warrants escalation of evaluation to uncover predisposing conditions. Children who experience more than three PBB episodes per year should undergo systematic assessment for structural, genetic, or immunologic contributors to persistent infection. This evaluation typically includes bronchoscopy with BAL to characterize airway microbiology and inflammation, high-resolution CT of the chest to assess for bronchiectasis or malacia, sweat testing to

screen for cystic fibrosis, and targeted immune function testing to detect antibody or cellular defects that increase infection risk [37]. Throughout both adult and pediatric pathways, the clinician should continuously integrate clinical response, imaging, and physiology to refine the working diagnosis, avoid unnecessary radiation or invasive testing, and prioritize early, guideline-concordant therapies that interrupt the cycle of mucus stasis, infection, and inflammation driving chronic bronchitic illness [7][35][36][37].

Treatment / Management

Effective treatment of chronic bronchitis requires an integrated approach that targets mucus pathobiology, modulates airway inflammation, restores mucociliary function, and equips patients with behavioral and rehabilitative tools to sustain lung health. Because chronic bronchitis and protracted bacterial bronchitis (PBB) are linked to accelerated respiratory decline and excess mortality, therapy must be proactive and longitudinal, not merely reactive to exacerbations. The foundational aim is to reduce excessive mucus production, diminish hypersecretion by attenuating inflammatory drivers, enhance ciliary transport to improve clearance, lower sputum viscosity, and support an effective cough. Central to this strategy is rigorous exposure control. Smoking cessation is the single most impactful intervention, as smoking and secondhand smoke disrupt ciliary beat frequency, injure epithelium, and promote goblet cell hyperplasia; cessation measurably improves mucociliary function and reduces airway injury [38]. The epidemiologic gradient underscores this priority: over 30 years, the cumulative incidence of chronic bronchitis is 42% in current smokers, 26% in former smokers, and 22% in never-smokers, quantifying the persistent risk even after quitting while affirming the clinical value of cessation at any stage [10]. Parallel counseling should address other irritants—biomass fuel exposure, occupational dusts and fumes, and indoor pollutants—to shrink the total inflammatory burden on the airway.

Chronic Bronchitis Management

Pharmacologic strategies to modify mucus and inflammation are variably endorsed across guidelines, and clinicians should navigate this heterogeneity with shared decision-making. Mucolytics such as N-acetylcysteine, carbocysteine, and erdosteine can reduce sputum tenacity and may facilitate clearance, but the American Academy of Chest Physicians advises against routine use of mucolytics, bronchodilators, or antibiotics for chronic cough in otherwise stable chronic bronchitis, emphasizing limited benefit in that specific context and discouraging nonpharmacologic devices such as positive end-expiratory pressure for routine management [39]. In contrast, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) suggests that chronic mucolytic therapy produces a modest, population-level reduction in exacerbations—on the order of roughly one fewer episode every three years—alongside small improvements in health status. Reconciling these positions, clinicians might consider a trial of mucolytics in patients with frequent exacerbations or refractory sputum viscoelasticity, while de-emphasizing them for stable, low-risk patients with isolated cough and minimal functional impact [39]. Management of acute exacerbations remains a critical competency because such events accelerate lung function decline and impair quality of life. Short-acting bronchodilators are first-line: albuterol delivered via nebulizer or metered-dose inhaler (MDI) is typically dosed every 20 minutes for two to three treatments, then every two to four hours as needed; delivery modality can be tailored to patient technique and severity, with nebulization offering pragmatic advantages for those with advanced COPD or poor MDI coordination. When needed, albuterol may be combined with the anticholinergic agent ipratropium bromide, recognizing that ipratropium alone is not preferred during the initial minutes of an exacerbation given its slower onset; maintenance dosing every four to six hours provides additive bronchodilation once the patient is stabilized. Patients with moderate to severe exacerbations should also receive systemic corticosteroids (e.g., prednisone 40 mg daily for five days), which shorten recovery time and reduce risk of treatment failure. Antibiotics are indicated when the classic cardinal features align: increased dyspnea, higher sputum volume, and new or worsened sputum purulence. The presence of all three symptoms strongly supports antibiotic therapy; a combination of any two, when one is sputum purulence, also justifies antibiotics [40][41] (A1). Duration should follow GOLD guidance, typically five days with reassessment, as prolonged courses do not improve outcomes for most patients [45][46].

Antibiotic therapy

Selecting an antibiotic requires balancing local resistance epidemiology, individual risk factors, and the probability of chronic *Pseudomonas aeruginosa* colonization. For average-risk patients—those without high-risk features or evidence of *Pseudomonas*—reasonable choices include a macrolide or an oral second- or third-generation cephalosporin such as cefuroxime or cefpodoxime, which provide adequate coverage for common pathogens in uncomplicated exacerbations. High-risk patients, by contrast, merit broader initial coverage: amoxicillin-clavulanate or a respiratory fluoroquinolone (levofloxacin or moxifloxacin) is appropriate for adults aged 65 and older, those with two or more COPD exacerbations or at least one COPD-related hospitalization in the prior 12 months, individuals with FEV_1 <50% predicted, or patients with significant comorbidities such as heart failure or ischemic heart disease, as well as those requiring continuous supplemental oxygen [42][43][44]. When

the clinical context or prior cultures suggest possible *Pseudomonas* colonization—particularly in patients with FEV_1 <30% predicted, radiographic bronchiectasis, recent broad-spectrum antibiotic exposure, or chronic systemic steroid use—empiric ciprofloxacin can be combined with sputum cultures to refine therapy once microbiology is known. In all scenarios, clinicians should aim for a five-day antibiotic course with formal reassessment; deviation toward longer therapy should be individualized, guided by clinical response and bacteriology rather than routine extension [40][41][45][46] (A1).

Other management considerations

Beyond bronchodilators and antimicrobials, anti-inflammatory adjuncts and rehabilitation play pivotal roles. Phosphodiesterase-4 inhibitors, most notably roflumilast, reduce exacerbation frequency in patients with severe COPD and chronic bronchitis phenotypes who have a history of exacerbations. By inhibiting PDE-4, roflumilast prevents cyclic adenosine monophosphate hydrolysis, dampening release of inflammatory mediators and exerting modest bronchodilatory effects. GOLD recommends considering roflumilast for patients with COPD and chronic bronchitis who have FEV_1 <50% predicted and at least one hospitalization for an exacerbation within the past year, particularly when exacerbations persist despite optimized inhaled therapy. Pulmonary rehabilitation is equally integral. A program of at least six weeks that includes supervised twice-weekly exercise training, structured self-management education, and psychosocial support improves dyspnea, exercise capacity, and health status while reducing hospitalizations in frequent exacerbators [47][48]. Rehabilitation also addresses the anxiety and depressive symptoms common in chronic respiratory disease, although access and cost remain barriers; tele-rehabilitation and community-based models may partially mitigate these limitations [47][48]. Across all interventions, inhaler technique assessment, adherence coaching, and exposure counseling should be revisited at every encounter, as incremental gains in self-management produce meaningful, cumulative benefits.

Protracted Bacterial Bronchitis

Treatment of PBB in children is anchored in sufficiently prolonged, guideline-concordant antibiotics to eradicate airway pathogens embedded within mucus and, at times, biofilm. American and European guidance recommends a minimum of two weeks of appropriate antibiotics, extending for an additional two weeks if the cough has not resolved by the end of the initial course, while British Thoracic Society guidance favors four to six weeks for all children, reflecting the tenacity of infection and the need to ensure full clinical resolution [7][8][9]. Amoxicillin-clavulanate is generally first-line due to reliable coverage of *Haemophilus influenzae* and *Streptococcus pneumoniae*. Acceptable alternatives include oral second- or third-generation cephalosporins, trimethoprim–sulfamethoxazole, or a macrolide, though azithromycin is discouraged in many settings because of rising resistance among *S. pneumoniae* and *H. influenzae*. Close follow-up at two and four weeks clarifies response; persistent wet cough after adequate therapy necessitates reconsideration of diagnosis, culture-directed treatment if bronchoalveolar lavage has been performed, or evaluation for complications such as early bronchiectasis. Children experiencing more than three PBB episodes in a single year warrant a broader search for predisposing conditions, including retained foreign body, cystic fibrosis, primary ciliary dyskinesia, and immunodeficiency. In such cases, bronchoscopy with BAL, sweat chloride testing, high-resolution chest CT, and targeted immune evaluation are appropriate to identify structural or host factors that sustain recurrent infection (A1). Counseling to eliminate passive smoke exposure and reduce environmental pollutants complements antimicrobial therapy by improving mucociliary defenses and lowering reinfection risk [7][8][9].

Vaccine Recommendations

Immunization is a cornerstone of prevention for patients with chronic lung disease, reducing the frequency and severity of respiratory infections that precipitate exacerbations. Annual influenza vaccination is recommended for all eligible patients and caregivers to minimize seasonal viral triggers. Pneumococcal vaccination strategies have evolved with expanded-valency conjugate formulations. Current guidance endorses either the 21-valent pneumococcal conjugate vaccine (PCV21) alone, the 20-valent PCV20 alone, or a sequence of the 15-valent PCV15 followed by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for adults aged 19 years and older with chronic lung disease [49]. PCV21 is preferred for most adults except those at increased risk for serotype 4, for whom PCV20 offers targeted coverage. PCV20 is specifically recommended for residents of the Navajo Nation and for individuals living in the Western United States and Canada who have substance use disorder or are experiencing homelessness due to regional sero-epidemiology. Adults who previously received only PPSV23, PPV10, or PPV13 should receive PCV21 or PCV20 at least one year after PPSV23; clinicians should consult the latest CDC schedules to tailor revaccination intervals and product selection to prior histories and risk groups, recognizing that recommendations are periodically updated [49]. In addition to pneumococcal and influenza vaccines, all eligible patients should receive the COVID-19 vaccine per contemporary schedules. Tetanus, diphtheria, and pertussis (Tdap) vaccination should follow the routine adult timetable, with boosters as indicated. Adults older than 60 years or those with chronic heart or lung disease are candidates for the respiratory syncytial virus (RSV) vaccine to mitigate severe lower respiratory tract illness and associated

hospitalizations. Finally, patients with COPD aged 50 and older should receive herpes zoster vaccination to prevent shingles and its pulmonary and systemic complications [50][51][52]. Vaccination counseling should be embedded into routine visits, inhaler checks, and pulmonary rehabilitation touchpoints to maximize uptake; documentation and reminder systems improve adherence to multi-dose schedules.

Across these domains—exposure control, exacerbation management, anti-inflammatory adjuncts, rehabilitation, pediatric-specific therapy, and immunization—the overarching principle is sustained, individualized care. Smoking cessation and environmental mitigation reduce the injurious inputs that perpetuate goblet cell hyperplasia and mucus hypersecretion [38]. Judicious use of mucolytics can be aligned with patient goals and risk profiles in light of differing recommendations [39]. Standardized, time-limited steroid and antibiotic protocols during exacerbations improve outcomes while curbing overtreatment [40][41][45][46]. For high-risk and *Pseudomonas*-prone patients, antibiotic selection should be culture-informed when possible and reassessed promptly in response to clinical change [42][43][44]. Roflumilast and comprehensive pulmonary rehabilitation address the inflammatory and functional consequences that pharmacotherapy alone cannot rectify [47][48]. In children with PBB, using adequately long antibiotic courses and escalating evaluation when relapses recur prevents evolution toward bronchiectasis [7][8][9]. Finally, broad vaccine coverage closes the loop by reducing infectious precipitants across seasons and life stages [49][50][51][52]. Together, these measures transform chronic bronchitis management from episodic crisis care into a preventive, multidisciplinary program that improves symptoms, preserves lung function, and reduces morbidity and mortality over the long term.

Differential Diagnosis

The evaluation of chronic bronchitis requires a systematic and comprehensive approach to exclude a wide range of pulmonary and extrapulmonary conditions that can present with chronic cough and sputum production. Since chronic bronchitis is a clinical diagnosis characterized by a productive cough lasting at least three months per year for two consecutive years, clinicians must first confirm that the chronicity criterion is met and then consider other disorders with overlapping manifestations. Acute bronchitis and acute sinusitis are frequent causes of transient productive cough, but these are self-limiting infections, typically resolving within weeks. A cough persisting beyond this period should prompt further evaluation for chronic etiologies [18]. Asthma and chronic obstructive pulmonary disease (COPD) remain among the most common mimics. Asthma-related cough may be dry or occasionally productive, accompanied by wheezing and variable airflow limitation, while COPD encompasses emphysematous and chronic bronchitic phenotypes that often coexist. Alpha-1 antitrypsin (AAT) deficiency must be excluded, particularly in younger patients or nonsmokers with airflow obstruction, as unrecognized genetic deficiency can lead to progressive emphysema [53]. Bronchiectasis and chronic suppurative lung disease present with daily purulent sputum and recurrent infections; high-resolution CT imaging can distinguish these conditions from chronic bronchitis by revealing airway dilatation and wall thickening. Cystic fibrosis, primary ciliary dyskinesia, and bronchomalacia or tracheomalacia should be considered in individuals with early-onset symptoms, recurrent pneumonia, or poor mucociliary clearance. Infectious diseases such as tuberculosis, pertussis, endemic fungal infections, and parasitic infections can produce chronic cough with sputum and systemic manifestations like fever, hemoptysis, or weight loss [54]. In endemic regions, diffuse panbronchiolitis also mimics chronic bronchitis but features chronic sinusitis and diffuse centrilobular nodules on imaging. Extrapulmonary contributors, including gastroesophageal reflux disease (GERD) and upper airway cough syndrome from chronic rhinosinusitis or postnasal drip, are frequent and must be excluded through clinical history, empiric trials, or diagnostic testing.

Cardiopulmonary conditions such as heart failure and pulmonary fibrosis may present with cough and dyspnea, though the cough is typically nonproductive. In addition, obstructive sleep apnea and postinfectious cough can perpetuate chronic cough through upper airway irritation. Medication effects, particularly from angiotensin-converting enzyme inhibitors, bisphosphonates, or calcium channel blockers, must be reviewed and managed appropriately. Neoplastic causes, including lung cancer, should be considered in high-risk individuals presenting with hemoptysis, weight loss, or a change in cough character, warranting chest imaging and further investigation [55]. Finally, immunodeficiency syndromes—whether congenital or acquired—predispose to recurrent infections and chronic airway inflammation that resemble chronic bronchitis. The diagnostic distinction among these conditions depends on integrating history, imaging, pulmonary function testing, laboratory evaluation, and therapeutic trials. Properly differentiating chronic bronchitis from these entities is crucial, as management strategies and prognostic implications vary significantly across this diverse spectrum of pulmonary and systemic disorders [18][53][54][55].

Prognosis

Chronic bronchitis conveys a substantive, age-spanning risk profile that encompasses accelerated decline in lung function, transition to fixed airflow obstruction, and increased all-cause mortality, even among younger adults and never-smokers. Longitudinal cohort data indicate that chronic

bronchitis symptoms are not merely epiphenomena of smoking or chronic obstructive pulmonary disease (COPD) but independent predictors of future impairment, with adults younger than 50 demonstrating heightened risks of mortality and subsequent COPD despite the absence of baseline obstruction [30]. The mechanistic underpinnings likely include a persistent inflammatory milieu that extends beyond the airway, as suggested by elevated systemic biomarkers such as interleukin-8 and C-reactive protein, which may contribute to cardiovascular comorbidity and broader frailty in affected individuals. Prognostic trajectories are shaped by a complex interplay of disease severity, patient age, genetic susceptibility, cumulative tobacco smoke exposure, coexisting conditions, and access to guideline-concordant care. Importantly, the presence of chronic bronchitic symptoms approximately doubles the risk of incident airflow obstruction compared with asymptomatic peers, underscoring the need for early recognition and risk modification [58]. Among smokers with chronic bronchitis, the outlook is further constrained by the high likelihood of progression to COPD, with roughly half eventually meeting diagnostic criteria, a statistic that crystallizes the centrality of smoking cessation as a disease-modifying intervention [58]. The quality-of-life penalty is substantial and durable: individuals with chronic bronchitis report persistent dyspnea, activity limitation, and social withdrawal, and they experience roughly double the number of COPD-related hospital days relative to those without the chronic bronchitis phenotype, reflecting a higher exacerbation burden and greater healthcare utilization [48][59]. Even partial risk mitigation yields measurable benefit; reductions in cigarette consumption alone have been associated with lifespan extension approaching 2.4 years, emphasizing that harm reduction confers incremental survival gains even when complete abstinence is not immediately achievable [10]. In pediatric populations, the prognostic arc differs but remains clinically consequential. Protracted bacterial bronchitis (PBB) generally carries a favorable outlook when treated promptly and adequately, yet delayed or incomplete therapy can permit progression to bronchiectasis with attendant morbidity and, over the life course, increased mortality risk [60]. Five-year follow-up data in children diagnosed with PBB reveal that approximately two-thirds continue to manifest symptoms and that nearly one in ten develop bronchiectasis, findings that argue for vigilant longitudinal follow-up, early culture-guided therapy when indicated, and timely involvement of pediatric pulmonology to prevent irreversible airway remodeling [61].

Complications

The complication profile of chronic bronchitis reflects both local airway pathology and systemic consequences of chronic inflammation and hypoxemia. Progressive airflow limitation and the evolution to COPD remain cardinal risks, but a broader spectrum of adverse outcomes requires equal attention. Recurrent exacerbations can precipitate acute respiratory failure, accelerate FEV_1 decline, and heighten the risk of death, while persistent mucus stasis fosters bacterial colonization and recurrent lower respiratory tract infections. Patients are susceptible to anxiety and depression, which compound symptom burden and may reduce adherence to therapy, thereby creating a feedback loop of worsening disease control. Cardiorenal crosstalk is clinically relevant: chronic bronchitis is associated with increased cardiac disease risk, and management must account for ischemic heart disease and heart failure that may present with or exacerbate dyspnea. Hemoptysis can occur in the setting of infection, bronchiectasis, or neoplasia, and the presence of copious or recurrent bleeding mandates evaluation for malignancy. Cor pulmonale and pulmonary hypertension arise from chronic hypoxic vasoconstriction and remodeling of the pulmonary vasculature, progressing to right ventricular strain and, in advanced cases, right heart failure. Secondary polycythemia may develop as a compensatory response to hypoxemia, increasing blood viscosity and thrombotic risk. Structural complications include pneumothorax in the setting of severe hyperinflation or concomitant bullous disease, while osteoporosis may result from inactivity and systemic corticosteroid exposure, incrementally raising fracture risk and deconditioning. Infections such as influenza and pneumococcal pneumonia occur more frequently and with greater severity, underscoring the preventive value of immunization in this population [62].

Patient Education

Because chronic bronchitis and PBB exert enduring effects on lung function and survival, prevention and patient activation are indispensable to any management plan. Education begins with clarifying the natural history of disease and the tangible benefits of risk-factor modification, particularly smoking cessation. Patients should receive clear, repeated counseling on the hazards of tobacco and the compounding effects of secondhand smoke; structured support that integrates pharmacotherapy, behavioral strategies, and follow-up has the highest likelihood of durable abstinence. Beyond tobacco, clinicians should help patients identify and reduce exposure to occupational dusts, fumes, and gases, as well as indoor pollutants and biomass fuels, which can perpetuate airway inflammation and mucus hypersecretion. Lifestyle guidance complements exposure control. Nutritional counseling focused on balanced caloric intake and adequate protein supports respiratory muscle function and mitigates cachexia in advanced disease, while hydration facilitates mucus rheology and clearance. Graduated exercise, ideally supervised within pulmonary rehabilitation programs, improves dyspnea, exercise capacity, and overall health status;

when center-based rehabilitation is inaccessible, home-based or tele-rehabilitation models can maintain momentum and adherence. Education on correct inhaler technique is essential, as suboptimal delivery undermines the benefits of even well-chosen regimens; periodic skills checks, spacers when appropriate, and device simplification improve outcomes. Patients should be taught to recognize early warning signs of exacerbation—rising cough frequency, increased sputum volume or purulence, and escalating breathlessness—and to act promptly through prearranged action plans that streamline access to care and appropriate rescue therapies. For children with PBB, caregivers need explicit instruction on antibiotic duration and the importance of follow-up to document cough resolution; incomplete courses risk relapse and structural damage. Across age groups, vaccination counseling should be routine, covering seasonal influenza, pneumococcal schedules, COVID-19 boosters, RSV vaccination where indicated, and age-appropriate herpes zoster immunization to reduce infection-triggered decompensation and hospitalization. In sum, early identification, continuous education, and practical self-management tools equip patients and families to participate actively in care, curtail progression, and improve long-term trajectories.

Enhancing Healthcare Team Outcomes

Optimal care for chronic bronchitis is inherently interprofessional, requiring coordination across primary care, pulmonology, pharmacy, nursing, respiratory therapy, rehabilitation, behavioral health, cardiology, and nutrition. Physicians and advanced practice clinicians synthesize history, imaging, and spirometry to establish diagnosis; adjudicate comorbidities such as asthma, heart failure, or sleep-disordered breathing; prescribe pharmacotherapy aligned with guideline-based pathways; and ensure that vaccines are current. Nurses operationalize education on inhaler technique, oxygen safety, vaccination, and smoking cessation while serving as navigators who identify barriers to access and adherence. Pharmacists select and reconcile medications, tailor inhaler platforms to patient capability, screen for drug–drug interactions, monitor for adverse effects, and lead antibiotic stewardship during exacerbations to balance efficacy with resistance mitigation. Respiratory therapists coach airway clearance techniques, evaluate oxygen needs, and assist with titration and delivery-system troubleshooting in home and acute settings. Physical therapists design and progress exercise regimens that improve functional capacity and reduce fall risk, while dieticians address energy balance, micronutrient sufficiency, and strategies to prevent or reverse respiratory cachexia. Behavioral health professionals treat anxiety, depression, and substance use disorders that often co-occur and influence disease control. The team's effectiveness hinges on reliable communication: shared care plans, closed-loop handoffs, and accessible documentation in the electronic health record prevent fragmentation and duplicated efforts. Structured follow-up schedules and remote monitoring—whether via symptom diaries, digital inhaler metrics, or telehealth—enable early detection of deterioration and timely intervention that may avert hospitalization. For pediatric PBB, coordinated pathways ensure that children who fail initial therapy or experience recurrent episodes receive expedited evaluation, including consideration of bronchoscopy, sweat testing, high-resolution CT, and immune assessment, with pediatric pulmonologists guiding imaging and culture-based management to prevent bronchiectasis. Across the continuum, explicit goals-of-care discussions, escalation plans for exacerbations, and caregiver education provide clarity during crises and reinforce engagement during stability. By aligning specialized skills and maintaining seamless communication, the interprofessional team can reduce exacerbation frequency, slow functional decline, and improve survival and quality-of-life metrics—outcomes that translate the science of chronic bronchitis into sustained, patient-centered progress [48][59][60][61][62][30][10][58].

Conclusion:

In conclusion, the effective management of chronic bronchitis and protracted bacterial bronchitis demands a fundamental shift from a siloed, episodic approach to a proactive, integrated, and interprofessional model. This paradigm recognizes these conditions as chronic diseases with significant long-term consequences, including accelerated lung function decline and increased mortality. The cornerstone of this model is the synergistic collaboration between clinical pharmacists, laboratory services, and health administrators. Pharmacists are pivotal in frontline patient engagement, optimizing medication regimens, and ensuring adherence, while laboratory services provide the essential microbiological data for precise, evidence-based antibiotic stewardship. Health administrators provide the critical scaffolding by designing standardized care pathways, implementing tracking registries, and allocating resources to support these initiatives. This collaborative framework ensures that care is continuous, patient-centered, and guideline-concordant. It enables the reliable administration of critical interventions, such as the two-week antibiotic course for PBB, and consistent patient education on smoking cessation and inhaler technique. By aligning these distinct yet complementary roles, healthcare systems can significantly improve key outcomes: reducing exacerbation frequency, preventing progression to bronchiectasis and COPD, and enhancing overall quality of life. Ultimately, embracing this team-based approach is essential for translating the growing understanding of bronchitic

pathophysiology into tangible, long-term benefits for patients across the lifespan.

References:

1. Zhang J, Wurzel DF, Perret JL, Lodge CJ, Walters EH, Dharmage SC. Chronic Bronchitis in Children and Adults: Definitions, Pathophysiology, Prevalence, Risk Factors, and Consequences. Journal of clinical medicine. 2024 Apr 20:13(8):. doi: 10.3390/jcm13082413.
2. Feng W, Zhang Z, Liu Y, Li Z, Guo W, Huang F, Zhang J, Chen A, Ou C, Zhang K, Chen M. Association of Chronic Respiratory Symptoms With Incident Cardiovascular Disease and All-Cause Mortality: Findings From the Coronary Artery Risk Development in Young Adults Study. Chest. 2022 Apr:161(4):1036-1045. doi: 10.1016/j.chest.2021.10.029.
3. Mejza F, Gnatiuc L, Buist AS, Vollmer WM, Lamprecht B, Obaseki DO, Nastalek P, Nizankowska-Mogilnicka E, Burney PGJ, BOLD collaborators, BOLD study collaborators. Prevalence and burden of chronic bronchitis symptoms: results from the BOLD study. The European respiratory journal. 2017 Nov:50(5):. doi: 10.1183/13993003.00621-2017.
4. Putcha N, Drummond MB, Connett JE, Scanlon PD, Tashkin DP, Hansel NN, Wise RA. Chronic productive cough is associated with death in smokers with early COPD. COPD. 2014 Aug:11(4):451-8. doi: 10.3109/15412555.2013.837870.
5. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax. 1990 Aug:45(8):57
6. de Marco R, Accordini S, Cerveri I, Corsico A, Antó JM, Künzli N, Janson C, Sunyer J, Jarvis D, Chinn S, Vermeire P, Svanes C, Ackermann-Liebrich U, Gislason T, Heinrich J, Leynaert B, Neukirch F, Schouten JP, Wjst M, Burney P. Incidence of chronic obstructive pulmonary disease in a cohort of young adults according to the presence of chronic cough and phlegm. American journal of respiratory and critical care medicine. 2007 Jan 1:175(1):32
7. Chang AB, Oppenheimer JJ, Irwin RS, CHEST Expert Cough Panel. Managing Chronic Cough as a Symptom in Children and Management Algorithms: CHEST Guideline and Expert Panel Report. Chest. 2020 Jul:158(1):303-329. doi: 10.1016/j.chest.2020.01.042.
8. Marchant JM, Petsky HL, Morris PS, Chang AB. Antibiotics for prolonged wet cough in children. The Cochrane database of systematic reviews. 2018 Jul 31:7(7):CD004822. doi: 10.1002/14651858.CD004822.pub3.
9. Shields MD, Bush A, Everard ML, McKenzie S, Primhak R, British Thoracic Society Cough Guideline Group. BTS guidelines: Recommendations for the assessment and management of cough in children. Thorax. 2008 Apr:63 Suppl 3():iii1-iii15
10. Pelkonen M, Notkola IL, Nissinen A, Tukiainen H, Koskela H. Thirty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest. 2006 Oct:130(4):1129-37
11. Dijkstra AE, de Jong K, Boezen HM, Kromhout H, Vermeulen R, Groen HJ, Postma DS, Vonk JM. Risk factors for chronic mucus hypersecretion in individuals with and without COPD: influence of smoking and job exposure on CMH. Occupational and environmental medicine. 2014 May:71(5):346-52. doi: 10.1136/oemed-2013-101654.
12. Rodríguez E, Ferrer J, Zock JP, Serra I, Antó JM, de Batlle J, Kromhout H, Vermeulen R, Donaire-González D, Benet M, Balcells E, Monsó E, Gayete A, Garcia-Aymerich J, PAC-COPD Study Group. Lifetime occupational exposure to dusts, gases and fumes is associated with bronchitis symptoms and higher diffusion capacity in COPD patients. PloS one. 2014:9(2):e88426. doi: 10.1371/journal.pone.0088426.
13. Pérez-Padilla R, Ramirez-Venegas A, Sansores-Martinez R. Clinical Characteristics of Patients With Biomass Smoke-Associated COPD and Chronic Bronchitis, 2004-2014. Chronic obstructive pulmonary diseases (Miami, Fla.). 2014 May 6:1(1):23-32. doi: 10.15326/jcopdf.1.1.2013.0004.
14. Lee JH, Cho MH, Hersh CP, McDonald ML, Crapo JD, Bakke PS, Gulsvik A, Comellas AP, Wendt CH, Lomas DA, Kim V, Silverman EK, COPDGene and ECLIPSE Investigators. Genetic susceptibility for chronic bronchitis in chronic obstructive pulmonary disease. Respiratory research. 2014 Sep 21:15(1):113. doi: 10.1186/s12931-014-0113-2.
15. Casara A, Turato G, Marin-Oto M, Semenzato U, Biondini D, Tinè M, Bernardinello N, Cocconcelli E, Cubero P, Balestro E, Spagnolo P, Marin JM, Cosio MG, Saetta M, Bazzan E. Chronic Bronchitis Affects Outcomes in Smokers without Chronic Obstructive Pulmonary Disease (COPD). Journal of clinical medicine. 2022 Aug 20:11(16):. doi: 10.3390/jcm11164886.
16. Gaude GS. Pulmonary manifestations of gastroesophageal reflux disease. Annals of thoracic medicine. 2009 Jul:4(3):115-23. doi: 10.4103/1817-1737.53347.
17. Ishak A, Everard ML. Persistent and Recurrent Bacterial Bronchitis-A Paradigm Shift in Our Understanding of Chronic Respiratory Disease. Frontiers in pediatrics. 2017:5():19. doi: 10.3389/fped.2017.00019.
18. Gallucci M, Pedretti M, Giannetti A, di Palmo E, Bertelli L, Pession A, Ricci G. When the Cough

Does Not Improve: A Review on Protracted Bacterial Bronchitis in Children. Frontiers in pediatrics. 2020:8():433. doi: 10.3389/fped.2020.00433.
19. Irwin RS, Curley FJ, French CL. Chronic cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. The American review of respiratory disease. 1990 Mar:141(3):640-7
20. Kim V, Criner GJ. The chronic bronchitis phenotype in chronic obstructive pulmonary disease: features and implications. Current opinion in pulmonary medicine. 2015 Mar:21(2):133-41. doi: 10.1097/MCP.0000000000000145
21. Dharmage SC, Perret JL, Burgess JA, Lodge CJ, Johns DP, Thomas PS, Giles GG, Hopper JL, Abramson MJ, Walters EH, Matheson MC. Current asthma contributes as much as smoking to chronic bronchitis in middle age: a prospective population-based study. International journal of chronic obstructive pulmonary disease. 2016:11():1911-20. doi: 10.2147/COPD.S103908.
22. Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. American journal of respiratory and critical care medicine. 2013 Feb 1:187(3):228-37. doi: 10.1164/rccm.201210-1843CI.
23. Senaratna CV, English DR, Currier D, Perret JL, Lowe A, Lodge C, Russell M, Sahabandu S, Matheson MC, Hamilton GS, Dharmage SC. Sleep apnoea in Australian men: disease burden, co-morbidities, and correlates from the Australian longitudinal study on male health. BMC public health. 2016 Oct 31:16(Suppl 3):1029. doi: 10.1186/s12889-016-3703-8.
24. Wurzel DF, Marchant JM, Yerkovich ST, Upham JW, Mackay IM, Masters IB, Chang AB. Prospective characterization of protracted bacterial bronchitis in children. Chest. 2014 Jun:145(6):1271-1278. doi: 10.1378/chest.13-2442.
25. O'Grady KF, Mahon J, Arnold D, Grimwood K, Hall KK, Goyal V, Marchant JM, Phillips N, Acworth J, King A, Scott M, Chang AB. Predictors of the Development of Protracted Bacterial Bronchitis following Presentation to Healthcare for an Acute Respiratory Illness with Cough: Analysis of Three Cohort Studies. Journal of clinical medicine. 2021 Dec 7:10(24):. doi: 10.3390/jcm10245735.
26. Nadel JA. Role of epidermal growth factor receptor activation in regulating mucin synthesis. Respiratory research. 2001:2(2):85-9
27. Kim S, Nadel JA. Role of neutrophils in mucus hypersecretion in COPD and implications for therapy. Treatments in respiratory medicine. 2004:3(3):147-59
28. Kesimer M, Ford AA, Ceppe A, Radicioni G, Cao R, Davis CW, Doerschuk CM, Alexis NE, Anderson WH, Henderson AG, Barr RG, Bleecker ER, Christenson SA, Cooper CB, Han MK, Hansel NN, Hastie AT, Hoffman EA, Kanner RE, Martinez F, Paine R 3rd, Woodruff PG, O'Neal WK, Boucher RC. Airway Mucin Concentration as a Marker of Chronic Bronchitis. The New England journal of medicine. 2017 Sep 7:377(10):911-922. doi: 10.1056/NEJMoa1701632.
29. Radicioni G, Ceppe A, Ford AA, Alexis NE, Barr RG, Bleecker ER, Christenson SA, Cooper CB, Han MK, Hansel NN, Hastie AT, Hoffman EA, Kanner RE, Martinez FJ, Ozkan E, Paine R 3rd, Woodruff PG, O'Neal WK, Boucher RC, Kesimer M. Airway mucin MUC5AC and MUC5B concentrations and the initiation and progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. The Lancet. Respiratory medicine. 2021 Nov:9(11):1241-1254. doi: 10.1016/S2213-2600(21)00079-5.
30. Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD. Chronic bronchitis before age 50 years predicts incident airflow limitation and mortality risk. Thorax. 2009 Oct:64(10):894-900. doi: 10.1136/thx.2008.110619.
31. Craven V, Everard ML. Protracted bacterial bronchitis: reinventing an old disease. Archives of disease in childhood. 2013 Jan:98(1):72-6. doi: 10.1136/archdischild-2012-302760.
32. Imran S, Shan M, Muazam S. A Comparative Histological Study of Submucosal Gland Hypertrophy in Trachea of Mice Exposed to Cigarette and Shisha Smoke. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP. 2018 Mar:28(3):192-195. doi: 10.29271/jcpsp.2018.03.192.
33. Badgett RG, Tanaka DJ, Hunt DK, Jelley MJ, Feinberg LE, Steiner JF, Petty TL. Can moderate chronic obstructive pulmonary disease be diagnosed by historical and physical findings alone? The American journal of medicine. 1993 Feb:94(2):188-96
34. Lemyze M, Bart F. Hoover sign. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2011 Feb 8:183(2):E133. doi: 10.1503/cmaj.092092.
35. Chang AB, Oppenheimer JJ, Weinberger MM, Rubin BK, Grant CC, Weir K, Irwin RS, CHEST Expert Cough Panel. Management of Children With Chronic Wet Cough and Protracted Bacterial Bronchitis: CHEST Guideline and Expert Panel Report. Chest. 2017 Apr:151(4):884-890. doi: 10.1016/j.chest.2017.01.025.

36. Chang AB, Upham JW, Masters IB, Redding GR, Gibson PG, Marchant JM, Grimwood K. Protracted bacterial bronchitis: The last decade and the road ahead. Pediatric pulmonology. 2016 Mar:51(3):225-42. doi: 10.1002/ppul.23351.
37. Chang AB, Oppenheimer JJ, Weinberger M, Rubin BK, Irwin RS. Children With Chronic Wet or Productive Cough--Treatment and Investigations: A Systematic Review. Chest. 2016 Jan:149(1):120-42. doi: 10.1378/chest.15-2065.
38. Mullen JB, Wright JL, Wiggs BR, Paré PD, Hogg JC. Structure of central airways in current smokers and ex-smokers with and without mucus hypersecretion: relationship to lung function. Thorax. 1987 Nov:42(11):843-8
39. Malesker MA, Callahan-Lyon P, Madison JM, Ireland B, Irwin RS, CHEST Expert Cough Panel. Chronic Cough Due to Stable Chronic Bronchitis: CHEST Expert Panel Report. Chest. 2020 Aug:158(2):705-718. doi: 10.1016/j.chest.2020.02.015.
40. Lee RA, Centor RM, Humphrey LL, Jokela JA, Andrews R, Qaseem A, Scientific Medical Policy Committee of the American College of Physicians, Akl EA, Bledsoe TA, Forciea MA, Haeme R, Kansagara DL, Marcucci M, Miller MC, Obley AJ. Appropriate Use of Short-Course Antibiotics in Common Infections: Best Practice Advice From the American College of Physicians. Annals of internal medicine. 2021 Jun:174(6):822-827. doi: 10.7326/M20-7355.
41. Llor C, Moragas A, Miravitlles M, Mesquita P, Cordoba G. Are short courses of antibiotic therapy as effective as standard courses for COPD exacerbations? A systematic review and meta-analysis. Pulmonary pharmacology & therapeutics. 2022 Feb:72():102111. doi: 10.1016/j.pupt.2022.102111
42. Sethi S, Murphy TF. Acute exacerbations of chronic bronchitis: new developments concerning microbiology and pathophysiology--impact on approaches to risk stratification and therapy. Infectious disease clinics of North America. 2004 Dec:18(4):861-82, ix
43. Gallego M, Pomares X, Espasa M, Castañer E, Solé M, Suárez D, Monsó E, Montón C. Pseudomonas aeruginosa isolates in severe chronic obstructive pulmonary disease: characterization and risk factors. BMC pulmonary medicine. 2014 Jun 26:14():103. doi: 10.1186/1471-2466-14-103.
44. Sethi S, Anzueto A, Miravitlles M, Arvis P, Alder J, Haverstock D, Trajanovic M, Wilson R. Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease. Infection. 2016 Feb:44(1):65-76. doi: 10.1007/s15010-015-0833-3.
45. Daubin C, Valette X, Thiollière F, Mira JP, Hazera P, Annane D, Labbe V, Floccard B, Fournel F, Terzi N, Du Cheyron D, Parienti JJ, BPCTrea Study Group. Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations of COPD admitted to the ICU: a randomized multicenter study. Intensive care medicine. 2018 Apr:44(4):428-437. doi: 10.1007/s00134-018-5141-9.
46. Kuijpers SME, Buis DTP, Ziesemer KA, van Hest RM, Schade RP, Sigaloff KCE, Prins JM. The evidence base for the optimal antibiotic treatment duration of upper and lower respiratory tract infections: an umbrella review. The Lancet. Infectious diseases. 2025 Jan:25(1):94-113. doi: 10.1016/S1473-3099(24)00456-0.
47. Blackstock FC, Lareau SC, Nici L, ZuWallack R, Bourbeau J, Buckley M, Durning SJ, Effing TW, Egbert E, Goldstein RS, Kelly W, Lee A, Meek PM, Singh S, American Thoracic Society, Thoracic Society of Australia and New Zealand, Canadian Thoracic Society, and British Thoracic Society. Chronic Obstructive Pulmonary Disease Education in Pulmonary Rehabilitation. An Official American Thoracic Society/Thoracic Society of Australia and New Zealand/Canadian Thoracic Society/British Thoracic Society Workshop Report. Annals of the American Thoracic Society. 2018 Jul:15(7):769-784. doi: 10.1513/AnnalsATS.201804-253WS.
48. Arkhipov V, Arkhipova D, Miravitlles M, Lazarev A, Stukalina E. Characteristics of COPD patients according to GOLD classification and clinical phenotypes in the Russian Federation: the SUPPORT trial. International journal of chronic obstructive pulmonary disease. 2017:12():3255-3262. doi: 10.2147/COPD.S142997.
49. Kobayashi M, Pilishvili T, Farrar JL, Leidner AJ, Gierke R, Prasad N, Moro P, Campos-Outcalt D, Morgan RL, Long SS, Poehling KA, Cohen AL. Pneumococcal Vaccine for Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2023 Sep 8:72(3):1-39. doi: 10.15585/mmwr.rr7203a1.
50. Boesing M, Albrich W, Bridevaux PO, Charbonnier F, Clarenbach C, Fellrath JM, Gianella P, Kern L, Latshang T, Pavlov N, Osthoff M, Steurer-Stey C, von Garnier C, Leuppi JD. Vaccination in adult patients with chronic lung diseases. Praxis. 2024 Dec:113(11-12):297-305. doi: 10.23785/PRAXIS.2024.11.003.
51. Kobayashi M, Leidner AJ, Gierke R, Farrar JL, Morgan RL, Campos-Outcalt D, Schechter R, Poehling KA, Long SS, Loehr J, Cohen AL. Use of 21-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR. Morbidity and mortality weekly report. 2024 Sep 12:73(36):793-

798. doi: 10.15585/mmwr.mm7336a3. Epub 2024 Sep 12
52. Grohskopf LA, Ferdinands JM, Blanton LH, Broder KR, Loehr J. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-25 Influenza Season. MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports. 2024 Aug 29:73(5):1-25. doi: 10.15585/mmwr.rr7305a1. Epub 2024 Aug 29
53. Chang AB, Oppenheimer JJ, Weinberger M, Weir K, Rubin BK, Irwin RS. Use of Management Pathways or Algorithms in Children With Chronic Cough: Systematic Reviews. Chest. 2016 Jan:149(1):106-19. doi: 10.1378/chest.15-1403.
54. Morice AH, Millqvist E, Bieksiene K, Birring SS, Dicpinigaitis P, Domingo Ribas C, Hilton Boon M, Kantar A, Lai K, McGarvey L, Rigau D, Satia I, Smith J, Song WJ, Tonia T, van den Berg JWK, van Manen MJG, Zacharasiewicz A. ERS guidelines on the diagnosis and treatment of chronic cough in adults and children. The European respiratory journal. 2020 Jan:55(1):. doi: 10.1183/13993003.01136-2019.
55. Chang AB, Oppenheimer JJ, Weinberger M, Grant CC, Rubin BK, Irwin RS, CHEST Expert Cough Panel. Etiologies of Chronic Cough in Pediatric Cohorts: CHEST Guideline and Expert Panel Report. Chest. 2017 Sep:152(3):607-617. doi: 10.1016/j.chest.2017.06.006. Epub 2017 Jun 21
56. Valipour A, Fernandez-Bussy S, Ing AJ, Steinfort DP, Snell GI, Williamson JP, Saghaie T, Irving LB, Dabscheck EJ, Krimsky WS, Waldstreicher J. Bronchial Rheoplasty for Treatment of Chronic Bronchitis. Twelve-Month Results from a Multicenter Clinical Trial. American journal of respiratory and critical care medicine. 2020 Sep 1:202(5):681-689. doi: 10.1164/rccm.201908-1546OC.
57. Bhatt SP, Rabe KF, Hanania NA, Vogelmeier CF, Bafadhel M, Christenson SA, Papi A, Singh D, Laws E, Patel N, Yancopoulos GD, Akinlade B, Maloney J, Lu X, Bauer D, Bansal A, Abdulai RM, Robinson LB, NOTUS Study Investigators. Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. The New England journal of medicine. 2024 Jun 27:390(24):2274-2283. doi: 10.1056/NEJMoa2401304.
58. Dotan Y, So JY, Kim V. Chronic Bronchitis: Where Are We Now? Chronic obstructive pulmonary diseases (Miami, Fla.). 2019 Apr 9:6(2):178-192. doi: 10.15326/jcopdf.6.2.2018.0151.
59. Pelkonen MK, Notkola IK, Laatikainen TK, Jousilahti P. Chronic bronchitis in relation to hospitalization and mortality over three decades. Respiratory medicine. 2017 Feb:123():87-93. doi: 10.1016/j.rmed.2016.12.018.
60. Wiltingh H, Marchant JM, Goyal V. Cough in Protracted Bacterial Bronchitis and Bronchiectasis. Journal of clinical medicine. 2024 Jun 4:13(11):. doi: 10.3390/jcm13113305.
61. Ruffles TJC, Marchant JM, Masters IB, Yerkovich ST, Wurzel DF, Gibson PG, Busch G, Baines KJ, Simpson JL, Smith-Vaughan HC, Pizzutto SJ, Buntain HM, Hodge G, Hodge S, Upham JW, Chang AB. Outcomes of protracted bacterial bronchitis in children: A 5-year prospective cohort study. Respirology (Carlton, Vic.). 2021 Mar:26(3):241-248. doi: 10.1111/resp.13950.
62. Braman SS. Chronic cough due to chronic bronchitis: ACCP evidence-based clinical practice guidelines. Chest. 2006 Jan:129(1 Suppl):104S-115S. doi: 10.1378/chest.129.1_suppl.104S. Epub.